Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2009-06-02
2011-11-22
Shameem, Golam M M (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S530000, C548S539000, C546S193000, C546S276400, C514S423000, C514S318000
Reexamination Certificate
active
08063075
ABSTRACT:
The present invention relates to compounds of formula Iwherein R1, R2, R3, R′, Ar, m, n, and o are as defined herein. The invention also relates to pharmaceutical compositions containing compounds of formula I and methods for the manufacture of such compounds and compositions. Compounds of the invention are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
REFERENCES:
patent: 7812021 (2010-10-01), Jablonski et al.
patent: 2005/0065210 (2005-03-01), Ackermann et al.
patent: 2006/0020011 (2006-01-01), Wu et al.
patent: 2006/298909 (2006-11-01), None
patent: WO 2006/016167 (2006-02-01), None
Tooney et al., Neurosci. Letters, 2000, 283, pp. 185-188.
Giardina et al., Exp. Opin. Ther. Patents, 2000, vol. 10, pp. 939-960.
Jung et al., Neuroscience, 1996, vol. 74, pp. 403-414.
Marco et al., Neuropeptides, 1998, vol. 32, pp. 481-488.
Kamali et al., Current Opinion in Investigational Drugs, 2001 vol. 2(7) pp. 950-956.
Belyk et al, Tet. Lett. 2004, vol. 45(16) pp. 3265-3268.
Albert et al., Exp. Opinion on Therapeutics Patents vol. 16(7) pp. 925-937 (2006).
Young, et al., Bioorganic & Med. Chem. Letters vol. 17(19) pp. 5310-5315 (2007).
Jablonski Philippe
Kawasaki Ken'ichi
Knust Henner
Limberg Anja
Nettekoven Matthias
Hoffmann-La Roche Inc.
Johnston George W.
Prior Kimberly J.
Rocha-Tramaloni Patricia S.
Shameem Golam M M
LandOfFree
Pyrrolidine ether derivatives as NK3 receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrolidine ether derivatives as NK3 receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolidine ether derivatives as NK3 receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4252744